Keywords
Last Name
Institution

Michael Mastrangelo

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8822
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. J Transl Med. 2017 Jun 23; 15(1):145. PMID: 28645290.
      View in: PubMed
    2. Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K, Dabbish N, Leiby B, Frank JA, Stitzenberg KB, Meyers MO. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. J Am Coll Surg. 2017 Apr; 224(4):652-659. PMID: 28189663.
      View in: PubMed
    3. Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol. 2016 Jan; 186(1):43-56. PMID: 26613897.
      View in: PubMed
    4. Mastrangelo MJ. The Last Chapter. Semin Oncol. 2015 Dec; 42(6):923-4. PMID: 26615137.
      View in: PubMed
    5. Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Nov; 2(11):1821-6. PMID: 26870807.
      View in: PubMed
    6. Feeney KJ, Mastrangelo MJ. Intralesional therapy for in-transit and satellite metastases in melanoma. Surg Oncol Clin N Am. 2015 Apr; 24(2):299-308. PMID: 25769713.
      View in: PubMed
    7. Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, Berd D, Mastrangelo MJ, Sato T. Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte-Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases. J Vasc Interv Radiol. 2015 Apr; 26(4):523-532.e2. PMID: 25678394.
      View in: PubMed
    8. Yoshida M, Selvan S, McCue PA, Deangelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2014 Mar; 27(2):297-308. PMID: 24354797.
      View in: PubMed
    9. Johnson C, Intenzo C, Mastrangelo MJ, Feeney K, Berger AC. Altered drainage patterns in patients with melanoma and previous axillary dissection. J Dermatol. 2013 Jul; 40(7):564-6. PMID: 23594177.
      View in: PubMed
    10. Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012 Dec; 22(6):440-6. PMID: 23114504.
      View in: PubMed
    11. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, HĂ„kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571; PMCID: PMC3338100.
    12. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011 Dec; 51(2-3):170-82. PMID: 22139852.
      View in: PubMed
    13. Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother. 2012 Feb; 61(2):145-55. PMID: 21853302.
      View in: PubMed
    14. Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, Hyslop T, Mastrangelo MJ. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol. 2012 Jan; 105(1):15-20. PMID: 21815149.
      View in: PubMed
    15. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45. PMID: 21519827.
      View in: PubMed
    16. Berencsi K, Rani P, Zhang T, Gross L, Mastrangelo M, Meropol NJ, Herlyn D, Somasundaram R. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med. 2011 Mar 30; 9:33. PMID: 21450101; PMCID: PMC3076246.
    17. Nair BC, Williams NC, Cui C, Summers D, Mastrangelo MJ, Hubosky SG, Shields CL, Shields JA, Sato T. Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol. 2011 Mar 20; 29(9):e216-9. PMID: 21189399.
      View in: PubMed
    18. Kaplan FM, Mastrangelo MJ, Aplin AE. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol. 2010 Nov; 130(11):2669-71. PMID: 20574441.
      View in: PubMed
    19. Marks JA, Rao AS, Loren D, Witkiewicz A, Mastrangelo MJ, Berger AC. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater. JOP. 2010; 11(2):173-5. PMID: 20208330.
      View in: PubMed
    20. Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol. 2010 Feb; 37(1):11-9. PMID: 20172358.
      View in: PubMed
    21. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009 Jul; 252(1):290-8. PMID: 19561263.
      View in: PubMed
    22. Mastrangelo MJ. Impact of malignant disease on young adults. Semin Oncol. 2009 Jun; 36(3):193. PMID: 19460576.
      View in: PubMed
    23. Terai M, Tamura Y, Alexeev V, Ohtsuka E, Berd D, Mastrangelo MJ, Sato T. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009 Aug; 58(8):1307-17. PMID: 19142637.
      View in: PubMed
    24. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008 Nov 20; 26(33):5436-42. PMID: 18838710.
      View in: PubMed
    25. Samplaski MK, Rosato EL, Witkiewicz AK, Mastrangelo MJ, Berger AC. Malignant melanoma of the gallbladder: a report of two cases and review of the literature. J Gastrointest Surg. 2008 Jun; 12(6):1123-6. PMID: 18060465.
      View in: PubMed
    26. Retsas S, Mastrangelo MJ. Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol. 2007 Dec; 34(6):491-7. PMID: 18083372.
      View in: PubMed
    27. Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007 Aug; 17(4):225-31. PMID: 17625452.
      View in: PubMed
    28. Mucci T, Long W, Witkiewicz A, Mastrangelo MJ, Rosato EL, Berger AC. Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg. 2007 Dec; 11(12):1755-7. PMID: 17619936.
      View in: PubMed
    29. Berd D, Mastrangelo MJ, Sato T. Calculation of survival of patients with stage III melanoma. J Clin Oncol. 2005 Dec 20; 23(36):9427; author reply 9428. PMID: 16361644.
      View in: PubMed
    30. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005 Aug; 15(4):297-304. PMID: 16034309.
      View in: PubMed
    31. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1; 22(3):403-15. PMID: 14691123.
      View in: PubMed
    32. Sato T, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother. 2004 Jan; 53(1):53-61. PMID: 13680192.
      View in: PubMed
    33. Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine. 2003 Apr 2; 21(15):1601-12. PMID: 12639481.
      View in: PubMed
    34. Herlyn D, Birebent B, Akis N, Purev E, Somasundaram R, Mitchell E, Maguire H, Staib L, Mastrangelo M. Colon cancer antigen and anti-idiotype vaccines. Cancer Chemother Biol Response Modif. 2003; 21:287-98. PMID: 15338751.
      View in: PubMed
    35. Reddy KS, Mastrangelo M, D Johnston T, Khan T, Waid T, McKeown W, Lucas B, Ranjan D. Recipient outcome following living donor kidney transplantation using kidneys procured laparoscopically. Clin Transplant. 2003; 17 Suppl 9:44-7. PMID: 12795668.
      View in: PubMed
    36. Mastrangelo MJ, Lattime EC. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. 2002 Dec; 9(12):1013-21. PMID: 12522440.
      View in: PubMed
    37. Manne J, Mastrangelo MJ, Sato T, Berd D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002 Sep 15; 169(6):3407-12. PMID: 12218163.
      View in: PubMed
    38. Berd D, Sato T, Mastrangelo MJ. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother. 2002 Aug; 51(6):320-6. PMID: 12111120.
      View in: PubMed
    Mastrangelo's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _